Get the Stockscreener App
4.63
4.99%
0.22
After Hours:
4.63
Recursion Pharmaceuticals Inc stock is traded at $4.63, with a volume of 10.57M.
It is up +4.99% in the last 24 hours and down -21.66% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$4.41
Open:
$4.46
24h Volume:
10.57M
Relative Volume:
0.26
Market Cap:
$2.38B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-2.9871
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
+11.03%
1M Performance:
-21.66%
6M Performance:
+5.35%
1Y Performance:
-27.43%
1-Day Range:
$4.40
$4.645
1-Week Range:
$4.145
$4.645
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.63 | 2.30B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Recursion Pharmaceuticals Gains Traction with Strategic Developments - timothysykes.com
Recursion Pharmaceuticals’ Advances Boost Market Confidence - timothysykes.com
Tangible book value per share of Recursion Pharmaceuticals, Inc. Class A – BIVA:RXRX - TradingView
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CFO Taylor Surrenders 2,271 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale - Investing.com
Recursion Pharmaceuticals Registers Resale of 7 Million Shares - TipRanks
Recursion Pharmaceuticals Registers Resale of Tempus Shares - TradingView
[8-K] RECURSION PHARMACEUTICALS, INC. Reports Material Event | RXRX SEC FilingForm 8-K - Stock Titan
Form 424B7 RECURSION PHARMACEUTICAL - StreetInsider
RXRX files prospectus for Tempus AI resale of 7.09M shares - Stock Titan
Is the Market Bullish or Bearish on Recursion Pharmaceuticals Inc? - Benzinga
A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail
Recursion Pharmaceuticals (RXRX): Evaluating Valuation After Fresh Leadership, Pharma Partnerships, and Market Optimism - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025 - ts2.tech
Top Biotech Stocks To Watch TodayNovember 21st - MarketBeat
Recursion (RXRX) Jumps 8% on Bargain-Hunting - Finviz
Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral
Recursion Pharmaceuticals Surpasses Third-Quarter Expectations, Announces Milestone with Roche - StocksToTrade
Recursion Pharmaceuticals Surges Amid CEO Transition and Strong Q3 Results - StocksToTrade
Soaring Stock: Recursion Pharmaceuticals’ Latest Surge - timothysykes.com
Recursion seeks to deliver results, and a VC sees a wave of M&A coming - statnews.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative
Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds? - Finviz
Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results - statnews.com
Recursion’s Khan Era: Proving AI Can Crack Drug Discovery - WebProNews
RXRX’s Anemic Revenue Misses Estimates - timothysykes.com
How Recursion Pharmaceuticals Inc. stock trades during market volatilityQuarterly Profit Report & Capital Efficiency Focused Strategies - newser.com
CFO Taylor Surrenders 11,908 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
Is Recursion Pharmaceuticals a Meme Stock? - MSN
How Recursion Pharmaceuticals Inc. stock reacts to bond yields2025 Biggest Moves & Trade Opportunity Analysis Reports - newser.com
CEO Gibson Files To Sell 40,000 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
Is Recursion Pharmaceuticals Inc. stock poised for growth2025 Analyst Calls & Fast Entry High Yield Stock Tips - newser.com
Recursion Pharmaceuticals (RXRX) Is Down 11.7% After Revenue Miss and CEO Transition – Has the Bull Case Changed? - simplywall.st
Will earnings trigger a reversal in Recursion Pharmaceuticals Inc.Analyst Downgrade & High Yield Stock Recommendations - newser.com
Recursion Pharmaceuticals, Inc.Class A Common Stock (NQ: RXRX - Markets Financial Content
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? (RXRX) - Seeking Alpha
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - MSN
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):